† Adverse events occurring in at least 2% of patients treated with memantine ER and at a rate that is higher than in the placebo group. SIB: significant benefit for memantine (LSMD: 2.6; 95% CI: 1.0–4 ...

The Food and Drug Administration approved the German medication memantine today to help ease the severe symptoms of an estimated 1 million Americans who suffer from the late stages of Alzheimer's ...

† Noted adverse events were experienced in ≥5% of either treatment group, and had an incidence more than or equal to twice as great in memantine-treated patients than in placebo-treated patients. AE: ...